Citation & Authors
Eur Heart J Cardiovasc Pharmacother. 2024;10(6):505-514.
ABSTRACT · RESEARCH SUMMARY
Research summary
This retrospective TriNetX study evaluated PCSK9-related lipid-lowering treatment using statin users as comparators. After matching, all-cause mortality was lower (aHR 0.717; 95% CI 0.673–0.763), as were hospitalization, emergency visits, intensive care, and mechanical ventilation. This was an observational comparison; treatment-selection differences and residual confounding may still influence the findings, which require confirmation in randomized trials.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
